Skip to main content

Investigation of the functions of a novel protein, PRDM16, rearranged in cases of acute myeloid leukaemia with rare translocations

Objective

The proposed research project plans to investigate the functions of a novel protein, PRDM16 (MEL1), in leukaemogenesis. PRDM16 is a member of the SET domain family of histone lysine methyltransferases and was recently identified by the host laboratory to be rearranged in three cases of acute myeloid leukaemia carrying rare translocations.

In the first case, full length PRDM16 is aberrantly expressed, whereas in the second case, a deleted PRDM16 lacking the SET domain (delPRDM16) is formed. In the third case, an AML1-PRDM16 fusion protein results. We plan to investigate how PRDM16, delPRDM16 and AML1-PRDM16 can give rise to AML. In particular we wish to investigate the importance of the SET domain, how fusion to AML1 alters the function of PRDM16, and whether AML1-PRDM16 can function in a similar way to AML1-ETO.

In vitro assays will initially be performed to investigate the biological phenotypes induced by each protein (PRDM16, delPRDM16, AML1-PRDM16 or AML1-ETO). The proteins will be over-expressed in murine haematopoietic progenitor cells (lin- cells) and will be assessed for their ability to block myeloid differentiation, increase survival upon genotoxic stress, and increase self-renewal.

In vivo assays will also be carried out to test the ability of the proteins to induce leukaemia in mice. In order to identify target genes commonly regulated by AML1-PRDM16 and AML1-ETO, Affymetrix gene expression microarrays will be employed. The proposed project will yield many important insights into the functions of PRDM16 and how its aberrant expression contributes to leukaemia.

The researcher has a background in mapping fusion genes in cancer and will therefore greatly expand her repertoire of laboratory skills by performing functional studies on a novel protein. The project will not only allow the researcher to become a highly skilled and independent scientist, but will make an important contribution to European cancer research.

Field of science

  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins
  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /natural sciences/biological sciences/genetics and heredity/mutation

Call for proposal

FP6-2002-MOBILITY-5
See other projects for this call

Funding Scheme

EIF - Marie Curie actions-Intra-European Fellowships

Coordinator

EUROPEAN INSTITUTE OF ONCOLOGY (ISTITUTO EUROPEO DI ONCOLOGIA)
Address
Via Filodrammatici, 10
Milano
Italy